These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29333565)

  • 1. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.).
    Hosono M; Ikebuchi H; Nakamura Y; Nakamura N; Yamada T; Yanagida S; Kitaoka A; Kojima K; Sugano H; Kinuya S; Inoue T; Hatazawa J
    Ann Nucl Med; 2018 Apr; 32(3):217-235. PubMed ID: 29333565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
    Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience.
    Das T; Chakraborty S; Kallur KG; Venkatesh M; Banerjee S
    Cancer Biother Radiopharm; 2011 Jun; 26(3):395-400. PubMed ID: 21728843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy.
    Das T; Banerjee S; Shinto A; Kamaleshwaran KK; Sarma HD
    Curr Radiopharm; 2014; 7(1):12-9. PubMed ID: 24934713
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
    Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials.
    Hosono M; Ikebuchi H; Kinuya S; Yanagida S; Nakamura Y; Yamada T; Sakaguchi K; Sugano H; Kojima K; Hatazawa J
    Ann Nucl Med; 2019 Nov; 33(11):787-805. PubMed ID: 31606788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
    Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
    Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
    Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3p-C-NETA: A versatile and effective chelator for development of Al
    Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
    Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
    [No Abstract]   [Full Text] [Related]  

  • 13. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Am J Clin Oncol; 2022 Jun; 45(6):233-242. PubMed ID: 35507413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
    Love C; Desai NB; Abraham T; Banks KP; Bodei L; Boike T; Brown RKJ; Bushnell DL; DeBlanche LE; Dominello MM; Francis T; Grady EC; Hobbs RF; Hope TA; Kempf JS; Pryma DA; Rule W; Savir-Baruch B; Sethi I; Subramaniam RM; Xiao Y; Schechter NR
    Clin Nucl Med; 2022 Jun; 47(6):503-511. PubMed ID: 35507433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of peptide receptor radionuclide therapy with
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
    Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
    [No Abstract]   [Full Text] [Related]  

  • 16. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
    Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours.
    de Araújo EB; Caldeira Filho JS; Nagamati LT; Muramoto E; Colturato MT; Couto RM; Pujatti PB; Mengatti J; Silva CP
    Appl Radiat Isot; 2009 Feb; 67(2):227-33. PubMed ID: 19027307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
    Wehrmann C; Senftleben S; Zachert C; Müller D; Baum RP
    Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.
    Seregni E; Maccauro M; Coliva A; Castellani MR; Bajetta E; Aliberti G; Vellani C; Chiesa C; Martinetti A; Bogni A; Bombardieri E
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):84-91. PubMed ID: 20168290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.